Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.9% to $3.1999 on volume of 196,096,419 shares Palantir Technologies Inc. Class A (PLTR) rose 9.8% to $26.14 on volume of 179,511,914 shares WiSA Technologies Inc. (WISA) fell 1...
2024-03-06 12:50:02 ET Gainers: Aptorum Group Ltd ( APM ) +736% . BiomX ( PHGE ) +144% . Trxade Health ( MEDS ) +87% . New Horizon Aircraft Ltd ( HOVR ) +69% . Rail Vision Ltd ( RVSN ) +62% . Airship AI Holdings ( AISP ) ...
2024-03-06 11:25:10 ET Over the past 3 months the biotech space is +30.4% and has only been outperformed by semiconductors, computer processing hardware and the computer peripherals industries. Additionally, the biotech sector is +13.6% in 2024, outdoing all of the major market aver...
2024-03-06 08:09:27 ET DENVER, Colo., Mar 06, 2024 ( 247marketnews.com )- BiomX Inc. (NYSE: PHGE ) stated, this morning, that it agreed to merge with Adaptive Phage Therapeutics, Inc. (“APT”), a privately-held, clinical-stage biotechnology company that’s based i...
2024-03-06 07:57:24 ET BiomX ( NYSE: PHGE ) shares climbed more than 100% in the premarket on Wednesday after the Israel-based company announced a stock-for-stock merger agreement with Adaptive Phage Therapeutics, a U.S.-based privately owned biotech.... Read the full arti...
Acquisition will create phage therapy company with an advanced pipeline with two P hase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis ( “ CF ” ) patients and BX 2 11 for the treatment of diabetic foot...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that its phage c...
2023-12-07 17:17:22 ET More on BiomX BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day BiomX mulls pivotal trial for antibacterial after Phase 1/2 data in cystic fibrosis For further details see: BiomX files for ...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...
2023-11-29 07:11:39 ET More on BiomX BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX F...
News, Short Squeeze, Breakout and More Instantly...
Chardan Healthcare Acquisition Corp. Company Name:
PHGE Stock Symbol:
NYSE Market:
Chardan Healthcare Acquisition Corp. Website:
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company&...
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...